1. A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer.
- Author
-
Zhang, KeJing, Wei, Juan, Zhang, SheYu, Fei, Liyan, Guo, Lu, Liu, Xueying, Ji, YiShuai, Chen, WenJun, Ciamponi, Felipe E., Chen, WeiChang, Li, MengXi, Zhai, Jie, Fu, Ting, Massirer, Katlin B., Yu, Yang, Lupien, Mathieu, Wei, Yong, Arrowsmith, Cheryl. H., Wu, Qin, and Tan, WeiHong
- Abstract
Paclitaxel-resistant triple negative breast cancer (TNBC) remains one of the most challenging breast cancers to treat. Here, using an epigenetic chemical probe screen, we uncover an acquired vulnerability of paclitaxel-resistant TNBC cells to protein arginine methyltransferases (PRMTs) inhibition. Analysis of cell lines and in-house clinical samples demonstrates that resistant cells evade paclitaxel killing through stabilizing mitotic chromatin assembly. Genetic or pharmacologic inhibition of PRMT5 alters RNA splicing, particularly intron retention of aurora kinases B (AURKB), leading to a decrease in protein expression, and finally results in selective mitosis catastrophe in paclitaxel-resistant cells. In addition, type I PRMT inhibition synergies with PRMT5 inhibition in suppressing tumor growth of drug-resistant cells through augmenting perturbation of AURKB-mediated mitotic signaling pathway. These findings are fully recapitulated in a patient-derived xenograft (PDX) model generated from a paclitaxel-resistant TNBC patient, providing the rationale for targeting PRMTs in paclitaxel-resistant TNBC. [Display omitted] • Paclitaxel-resistant triple-negative breast cancer is vulnerable to PRMTs inhibition • Inhibiting type I PRMTs and PRMT5 synergizes to suppress paclitaxel-resistant TNBC growth • Targeting PRMTs induces intron retention in AURKB, leading to mitotic catastrophe Paclitaxel-resistant triple-negative breast cancer (TNBC) remains challenging to treat. Zhang et al. discover that resistant TNBC cells are vulnerable to PRMT inhibition, which decreases AURKB protein levels and induces mitotic catastrophe. Inhibiting type I PRMTs and PRMT5 synergizes to suppress tumor growth, suggesting a promising strategy for treating paclitaxel-resistant TNBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF